 Connection
Guido Tricot to Doxorubicin
This is a "connection" page, showing publications Guido Tricot has written about Doxorubicin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.460 |
|
|
|
-
Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15; 100(4):1168-71.
Score: 0.192
-
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
Score: 0.051
-
Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
Score: 0.051
-
Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma. 2002 Jun; 43(6):1267-71.
Score: 0.047
-
Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8.
Score: 0.047
-
Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152.
Score: 0.037
-
Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009 Jul; 20(5):337-9.
Score: 0.019
-
van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|